Osteoporosis and diabetes

被引：74

作者：

Diane L. Chau

Steven V. Edelman

Manju Chandran

机构：

[1] Department of Geriatric Medicine, VA Sierra Health Care Systems, Univ. of Nevada School of Medicine, Reno, NV 89502

来源：

Current Diabetes Reports | 2003年 / 3卷 / 1期

关键词：

Bone Mineral Density; Osteoporosis; Alendronate; Zoledronic Acid; Raloxifene;

D O I：

10.1007/s11892-003-0051-8

中图分类号：

学科分类号：

摘要：

Osteoporosis is the most prevalent metabolic bone disease in the United States. Although the disease has historically been reported mostly in white women, it can affect individuals of both sexes and all ethnic groups. The presence of osteoporosis related to diabetes is not well acknowledged and the impact of osteoporosis in a diabetic patient is often not considered. Routine screening or initiation of preventive medications for osteoporosis in all patients with type 1 or type 2 diabetes is not recommended at the present time. However, in all patients with diabetes, besides optimal glycemic control, general recommendations regarding adequate dietary calcium intake, regular exercise, and avoidance of other potential risk factors such as smoking should be given. In patients who have positive risk factors for osteoporosis, or in those who present with fractures, evaluation of bone density should be done and respective preventive or therapeutic interventions should be applied. Copyright © 2003 by Current Science Inc.

引用

页码：37 / 42

页数：5

共 49 条

[1] Assessment of Fracture Risk and Its Application to Screening for Postmenopausal Osteoporosis Report of a WHO Study Group, (1994)
[2] Looker A.C., Johnston Jr. C.C., Wahner H.W., Et al., Prevalence of low femoral bone density in older U.S. women from NHANES III, J. Bone Miner. Res., 10, pp. 796-802, (1995)
[3] Ray N.F., Chan J.K., Thamer M., Melton III L.J., Medical expenditures for the treatment of osteoporotic fracture in the United States in 1995: Report from the National Osteoporosis Foundation, J. Bone Miner. Res., 12, pp. 24-35, (1997)
[4] Wu F., Mason B., Horne A., Et al., Fractures between the ages of 20 and 50 years increase women's risk of subsequent fractures, Arch. Intern. Med., 162, pp. 33-36, (2002)
[5] Siris E.S., Miller P.D., Barrett-Connor E., Et al., Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: Results from the National Osteoporosis Risk Assessment, JAMA, 286, pp. 2815-2822, (2001)
[6] Cooper C., Atkinson E.J., Jacobsen S.J., Et al., Population-based study of survival after osteoporotic fractures, Am. J. Epidemiol., 137, pp. 1001-1005, (1993)
[7] Nightingale S., Holmes J., Mason J., House A., Psychiatric illness and mortality after hip fracture, Lancet, 357, pp. 1264-1264, (2001)
[8] Risk assessment
[9] Forsen L., Meyer H.E., Midthjell K., Edna T.H., Diabetes mellitus and the incidence of hip fracture: Results from the Nord-Trondelag Health Survey, Diabetologia, 42, pp. 920-925, (1999)
[10] Nicodemus K.K., Folsom A.R., Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women, Diabetes Care, 24, pp. 1192-1197, (2001)

← 1 2 3 4 5 →